• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Infectious Disease

H1N1 influenza vaccination not associated with congenital malformations

byQasim HussainiandDeepti Shroff
September 20, 2016
in Infectious Disease, Obstetrics, Pediatrics, Public Health
Reading Time: 3 mins read
Decreased prevalence of HPV among vaccinated young females
Share on FacebookShare on Twitter

1. H1N1 vaccination is not linked with increased risk for overall congenital malformations.

2. Risk increases for specific malformations could not be ruled out.

Evidence Rating Level: 1 (Excellent)

Study Rundown: During the 2009 H1N1 influenza epidemic, approximately 200 million individuals worldwide were effected and several national vaccination campaigns initiated. Previous studies have investigated a relationship between the vaccination of pregnant women and subsequent congenital malformation in the offspring. While most demonstrated mixed evidence, several studies did not consider the potential role of confounding error that may occur due to genetic and shared environmental factors.

In this population-based prospective cohort study, registry data from seven Swedish health centers comprising approximately 60% of the country’s population were obtained. Approximately 40,983 of the offspring were prenatally exposed to the government-sponsored AS03-adjuvanted monovalent vaccine (Pandemrix), with 14,385 in the first trimester and 7,502 in the first 8 weeks when the risk of congenital malformations may be highest. Overall, no increased risk was found between the exposed and unexposed offspring. Further, no statistically significant risk differences were found in a separate sibling analysis. In a subgroup analysis, however, a significant relationship between the risk of oral cleft and vaccine exposure was present. The current study includes more Pandemrix-exposed offspring compared to previous studies, successfully eliminates recall bias related errors, and examines the potential effects of confounding.

Overall, the study suggests H1N1 vaccination is not associated with congenital malformations when intrafamilial factors are taken into consideration. Limitations include malformations occurring in prior pregnancies that may influence the decision to be vaccinated during the study period. The study was also based on live births and cannot dismiss miscarriage or stillbirths caused by congenital malformations. Future studies should consider H1N1 vaccination increasing the risk of specific malformations.

RELATED REPORTS

First messenger RNA influenza vaccine outperforms standard-dose vaccination

2MM: Pharma Roundup – mRNA flu vaccine debuts, RAS inhibition extends pancreatic cancer survival, and new therapies advance for dermatomyositis and Tourette syndrome

mFlusiva becomes the first mRNA influenza vaccine approved by the FDA

Click to read the study, published in the Annals of Internal Medicine

Relevant Reading: Influenza vaccination during pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safe outcomes

In-Depth [prospective cohort]: Registry data on influenza A(H1N1)pdm09 vaccinations administered between 2009 and 2010 were linked to pregnant women during the pandemic, pregnancy characteristics, and malformation data. Vaccination during the first trimester and in the first 8 weeks of pregnancy were examined. Controls comprised of pregnancies during the same period but without recorded influenza A(H1N1)pdm09 vaccination. Swedish Medical Birth Register was utilized to obtain most covariate and pregnancy data, and the Swedish Total Population Register was used to identify siblings of offspring that were prenatally exposed to the vaccine during pregnancy. Congenital malformation was the main outcome measure and these were examined in offspring born between 1 October 2009 to 1 October 2011, approximately the period between the start of the campaign and 9 months after the end of the campaign (n = 97,869; 40,983 exposed and 56,886 unexposed).

About 4.98% and 4.96% were the adjusted risks in the exposed and unexposed offspring. Only malformations during the first year of life were included. The sibling comparators were born between 2001 and 2011. All exposed offspring together with their siblings were used in the study (n = 5597; 2383 exposed and 3214 unexposed). Adjusted odds ratio for any malformation was 0.98 (CI 0.89 to 1.07) for a full pregnancy and 1.03 (CI 0.88 to 1.19) for the first trimester. A subanalysis measured the risk of congenital heart disease, oral cleft, and limb deficiency. In this analysis, risk differences during the first 8 weeks of pregnancy were 0.12% for CHD, 0.10% for oral cleft and 0.02% for limb deficiency.

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Influenza vaccine
Previous Post

Hospitals are employing more physicians, but this does not necessarily improve care

Next Post

Azithromycin not effective in acute asthma exacerbations: The AZALEA trial

RelatedReports

Pharma

First messenger RNA influenza vaccine outperforms standard-dose vaccination

September 15, 2026
Pharma Roundup

2MM: Pharma Roundup – mRNA flu vaccine debuts, RAS inhibition extends pancreatic cancer survival, and new therapies advance for dermatomyositis and Tourette syndrome

September 15, 2026
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Pharma

mFlusiva becomes the first mRNA influenza vaccine approved by the FDA

August 26, 2026
Social networks play key roles in parental vaccination decisions
Infectious Disease

Concomitant COVID-19 and influenza vaccination not linked to increased adverse events

June 29, 2026
Next Post
Microbe-rich environment associated with lower rates of asthma

Azithromycin not effective in acute asthma exacerbations: The AZALEA trial

HOSPITAL score predicts risk of 30-day potentially avoidable readmission to hospital

Total inpatient antibiotic use consistent from 2006 to 2012

Digital imaging detects sight-threatening retinopathy of prematurity

CPAP is superior to nasal high-flow therapy as primary support for preterm infants

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Artificial intelligence (AI) scribes showed mixed effects on documentation time and improvements in physician well-being
  • A lower threshold for referral to the emergency department for outpatient hyperkalemia may reduce mortality
  • Ecopipam reduces relapse risk in pediatric Tourette syndrome
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.